The fetal safety of fluoxetine: a systematic review and meta-analysis

• Published in: Journal of obstetrics and gynaecology Canada Vol. 35; no. 4; p. 362
• Main Authors: Riggin, Lauren, Frankel, Zipora, Moretti, Myla, Pupco, Anna, Koren, Gideon
• Format: Journal Article
• Language: English
• Published: Netherlands 01.04.2013
• Subjects: Abnormalities, Drug-Induced - epidemiology; Abnormalities, Drug-Induced - etiology; Case-Control Studies; Cohort Studies; Depression - complications; Depression - drug therapy; Female; Fluoxetine - adverse effects; Heart Defects, Congenital - chemically induced; Heart Defects, Congenital - epidemiology; Humans; MEDLINE; Odds Ratio; Pregnancy; Pregnancy Complications - psychology; Pregnancy Trimester, First; Selective Serotonin Reuptake Inhibitors - adverse effects; meta-analysis; malformations; selective serotonin reuptake inhibitor; fluoxetine; SSRIs; pregnancy

Fluoxetine is the selective serotonin reuptake inhibitor (SSRI) with the longest clinical use. Published reports regarding its fetal safety are contradictory. We aimed to establish the fetal safety of the drug. We performed a systematic review of the literature, searching PubMed, Medline, and Embase...